Millipred Shortage: What Providers and Prescribers Need to Know in 2026

Prednisolone — the active ingredient in Millipred — has been experiencing intermittent supply disruptions since 2020, with the oral liquid formulation most significantly affected. As a prescriber, you're likely fielding calls from patients who can't fill their prescriptions and from pharmacists requesting therapeutic substitutions. This briefing provides a current assessment of the supply landscape, practical prescribing guidance, and tools to help your patients maintain access to treatment.

Current Supply Status (2026)

As of 2026, prednisolone oral solution supply remains inconsistent:

Prednisolone oral solution (15 mg/5 mL): Most affected formulation. Has appeared intermittently on the FDA Drug Shortage Database since 2020. Supply gaps continue, particularly during respiratory illness season (October–March).

Prednisolone oral solution (10 mg/5 mL): The Millipred-branded concentration. Localized availability issues occur; generally more available than 15 mg/5 mL.

Prednisolone tablets (5 mg): Generally available. Consider pivoting liquid prescriptions to tablets for patients who can swallow them.

The structural drivers — limited manufacturer base, low profit margins for generic liquid formulations, complex manufacturing requirements, and seasonal demand variability — are unlikely to resolve quickly. Providers should plan for continued intermittent supply disruptions through at least 2026–2027.

Therapeutic Substitution Options

When prednisolone is unavailable, the following substitution strategies are clinically appropriate for most indications:

Corticosteroid Dose Equivalencies

The following approximate equivalencies reflect anti-inflammatory potency:

Prednisolone 5 mg = Prednisone 5 mg = Methylprednisolone 4 mg = Dexamethasone 0.75 mg = Hydrocortisone 20 mg

Important: These equivalencies reflect anti-inflammatory potency only. Mineralocorticoid effects, duration of action, and clinical context must inform the choice of agent. Dexamethasone's long half-life (36–72 hours) makes it less suitable for alternate-day tapering regimens compared to prednisolone or prednisone.

Substitution by Clinical Scenario

Adult oral anti-inflammatory therapy: Prednisone is the most direct substitute. Nearly universally available, equivalent anti-inflammatory efficacy at equal mg dosing. Suitable for patients with normal hepatic function.

Patients with significant hepatic dysfunction: Prednisolone is the preferred agent because it does not require hepatic bioactivation. If unavailable, discuss options with the patient's hepatologist.

Pediatric oral liquid (croup, asthma flare): Dexamethasone oral solution has become a widely accepted alternative. Single-dose dexamethasone (0.15–0.6 mg/kg) has demonstrated efficacy comparable to multi-dose prednisolone for croup. Updated clinical guidance supports this substitution.

Nephrotic syndrome (pediatric): Prednisolone is the recommended first-line agent per KDIGO and AAP guidelines. If unavailable, consult pediatric nephrology before substituting.

Long-term anti-inflammatory therapy: Consider whether tablets are feasible for the patient. Prednisolone tablets (5 mg) are generally available and avoid the liquid shortage problem entirely.

Prescribing Considerations During Shortage Periods

Prescribe by generic name: Writing 'prednisolone oral solution' rather than 'Millipred' gives pharmacies maximum sourcing flexibility across available manufacturers.

Allow therapeutic substitution on the prescription: Including a note like 'May substitute dexamethasone per pharmacist consultation if prednisolone unavailable' reduces the friction of callback approvals during shortages.

Issue prescriptions to multiple pharmacies simultaneously: For patients with urgent need, consider issuing multiple prescriptions (or electronic prescriptions to multiple pharmacies) so the patient can fill at whichever location has stock.

Refer to compounding pharmacies: Many compounding pharmacies stock prednisolone API and can prepare oral solution on demand. Establish a working relationship with a local PCAB-accredited compounder before the next shortage peak.

Communicating the Shortage to Patients

Patients who can't fill their prescription are often confused and anxious. A few communication points to share:

The shortage is nationwide and not the result of a recall or safety issue.

Effective alternatives are available and you can help them switch if needed.

They should not stop prednisolone abruptly if on long-term therapy — taper guidance is critical.

Tools like medfinder for Providers can help patients search pharmacies near them without calling each one individually.

For a complete provider guide to helping patients find Millipred, see how to help your patients find Millipred in stock.